{"id":"https://openalex.org/W1968644601","doi":"https://doi.org/10.1007/s002280000224","title":"Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor","display_name":"Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor","publication_year":2001,"publication_date":"2001-01-01","ids":{"openalex":"https://openalex.org/W1968644601","doi":"https://doi.org/10.1007/s002280000224","mag":"1968644601","pmid":"https://pubmed.ncbi.nlm.nih.gov/11294370"},"language":"en","primary_location":{"id":"doi:10.1007/s002280000224","doi":"https://doi.org/10.1007/s002280000224","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s002280000224","pdf_url":null,"source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111754267","display_name":"Katy H. P. Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K.H.P. Moore","raw_affiliation_strings":["Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, UK. km10993@glaxowellcome.com","Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex, UK. km10993@glaxowellcome.com","institution_ids":[]},{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064099926","display_name":"Lindsey Cass","orcid":"https://orcid.org/0000-0003-3719-0883","observed_orcids":["https://orcid.org/0000-0003-3719-0883"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L.M. Cass","raw_affiliation_strings":["Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","institution_ids":[]},{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045220307","display_name":"Nigel S. Dallow","orcid":"https://orcid.org/0000-0002-1678-0561","observed_orcids":["https://orcid.org/0000-0002-1678-0561"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Dallow","raw_affiliation_strings":["Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","institution_ids":[]},{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008698796","display_name":"Timothy Colin Hardman","orcid":"https://orcid.org/0000-0002-1417-9019","observed_orcids":["https://orcid.org/0000-0002-1417-9019"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T.C. Hardman","raw_affiliation_strings":["Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","institution_ids":[]},{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086142","display_name":"Zimmer Biomet (United Kingdom)","ror":"https://ror.org/00mke2t69","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210086142","https://openalex.org/I4210115238"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Jones","raw_affiliation_strings":["International Bioanalysis, Biomet, Glaxo Wellcome Research and Development, Park Road, Ware, Hertsfordshire, SG12 0DJ, UK, UK","International Bioanalysis, Biomet, Glaxo Wellcome Research and Development, Park Road, Ware, Hertsfordshire, SG12 0DJ, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"International Bioanalysis, Biomet, Glaxo Wellcome Research and Development, Park Road, Ware, Hertsfordshire, SG12 0DJ, UK, UK","institution_ids":["https://openalex.org/I4210086142"]},{"raw_affiliation_string":"International Bioanalysis, Biomet, Glaxo Wellcome Research and Development, Park Road, Ware, Hertsfordshire, SG12 0DJ, UK","institution_ids":["https://openalex.org/I4210086142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038870948","display_name":"Malcolm J. Boyce","orcid":"https://orcid.org/0000-0001-8807-612X","observed_orcids":["https://orcid.org/0000-0001-8807-612X"]},"institutions":[{"id":"https://openalex.org/I4210093621","display_name":"Hammersmith Medicines Research","ror":"https://ror.org/00hj12c83","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210093621"]},{"id":"https://openalex.org/I4210131790","display_name":"Central Middlesex Hospital","ror":"https://ror.org/03mq8zc85","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800484787","https://openalex.org/I4210131790"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Boyce","raw_affiliation_strings":["Hammersmith Medicines Research, Central Middlesex Hospital, Park Road, London, NW10 7NS, UK, UK","Hammersmith Medicines Research, Central Middlesex Hospital, Park Road, London, NW10 7NS, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hammersmith Medicines Research, Central Middlesex Hospital, Park Road, London, NW10 7NS, UK, UK","institution_ids":["https://openalex.org/I4210093621","https://openalex.org/I4210131790"]},{"raw_affiliation_string":"Hammersmith Medicines Research, Central Middlesex Hospital, Park Road, London, NW10 7NS, UK","institution_ids":["https://openalex.org/I4210093621","https://openalex.org/I4210131790"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022472681","display_name":"William Prince","orcid":"https://orcid.org/0009-0000-5341-6382","observed_orcids":["https://orcid.org/0009-0000-5341-6382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W.T. Prince","raw_affiliation_strings":["Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK, UK","institution_ids":[]},{"raw_affiliation_string":"Department of Clinical Pharmacology, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 0HE, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":null,"fwci":0.7365,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.70686908,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"56","issue":"11","first_page":"805","last_page":"811"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.953000009059906},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6050000190734863},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.7289999723434448},{"id":"https://openalex.org/keywords/accumulation","display_name":"accumulation","score":0.48500001430511475},{"id":"https://openalex.org/keywords/oral-clearance","display_name":"oral clearance","score":0.7390000224113464},{"id":"https://openalex.org/keywords/steady-state-pharmacokinetics","display_name":"steady-state pharmacokinetics","score":0.6859999895095825},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7419999837875366},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5350000262260437},{"id":"https://openalex.org/keywords/hiv-antiretroviral-therapy","display_name":"HIV antiretroviral therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.3630000054836273},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.9070000052452087},{"id":"https://openalex.org/keywords/qtc-prolongation","display_name":"QTc prolongation","score":0.49399998784065247},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.4480000138282776}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8139750957489014},{"id":"https://openalex.org/C2909970146","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Nucleoside Reverse Transcriptase Inhibitor","level":5,"score":0.6972531080245972},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.6318920254707336},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.5970651507377625},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5715363621711731},{"id":"https://openalex.org/C2777333352","wikidata":"https://www.wikidata.org/wiki/Q2689559","display_name":"Nucleoside analogue","level":3,"score":0.5165395140647888},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.426051527261734},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.416654109954834},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3750946521759033},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.14314311742782593},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.12189584970474243},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007408","descriptor_name":"Intestinal Absorption","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s002280000224","doi":"https://doi.org/10.1007/s002280000224","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s002280000224","pdf_url":null,"source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:11294370","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11294370","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2131499894","https://openalex.org/W1971248628","https://openalex.org/W2047039915","https://openalex.org/W7096810233","https://openalex.org/W2032012062","https://openalex.org/W2398688051","https://openalex.org/W2122778067","https://openalex.org/W4414263677","https://openalex.org/W2006341662","https://openalex.org/W1967763477"],"abstract_inverted_index":null,"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}